Evidence map›Paper›PMID 30716120›Full record

ArticlePloS one2019

AMPA receptor antagonist perampanel affects glioblastoma cell growth and glutamate release in vitro.

Falko Lange, Konrad Weßlau, Katrin Porath, Max Frederik Hörnschemeyer, Carina Bergner, Bernd Joachim Krause, Christina Susanne Mullins, Michael Linnebacher, Rüdiger Köhling, Timo Kirschstein

Open access · goldAbstract read
In one paragraph

Article in PloS one, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 55 papers.

0numbers the graph read from it
0cells of the map it votes in
55citing papers in PubMed
5.6field-weighted citation impact, top 4% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

55 citing papers in PubMed, 93 citations in OpenAlex.

  1. Trial
  2. Observational
  3. Article
  4. Article
  5. Review
  6. Review
  7. Review
  8. Review
  9. Observational
  10. Review
  11. Review
  12. Review
  13. The molecular landscape of glioblastoma-associated epilepsy.Journal of molecular medicine (Berlin, Germany) · 2025
    Review
  14. Article
  15. Review
  16. Review
  17. Review
  18. Article
  19. Epilepsy in Patients with Gliomas.Neurologia medico-chirurgica · 2024
    Review
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors at 1 institution in 1 country.

Falko LangeOscar-Langendorff-Institute of Physiology, Rostock University Medical Center, Rostock, Germany.ORCID 0000-0001-8782-5205
Konrad WeßlauOscar-Langendorff-Institute of Physiology, Rostock University Medical Center, Rostock, Germany.
Katrin PorathOscar-Langendorff-Institute of Physiology, Rostock University Medical Center, Rostock, Germany.
Max Frederik HörnschemeyerOscar-Langendorff-Institute of Physiology, Rostock University Medical Center, Rostock, Germany.
Carina BergnerDepartment of Nuclear Medicine, Rostock University Medical Center, Rostock, Germany.
Bernd Joachim KrauseCenter for Transdisciplinary Neurosciences Rostock, University of Rostock, Rostock, Germany.
Christina Susanne MullinsDepartment of Surgery, Rostock University Medical Center, Rostock, Germany.ORCID 0000-0003-2296-2027
Michael LinnebacherDepartment of Surgery, Rostock University Medical Center, Rostock, Germany.
Rüdiger KöhlingOscar-Langendorff-Institute of Physiology, Rostock University Medical Center, Rostock, Germany.
Timo KirschsteinOscar-Langendorff-Institute of Physiology, Rostock University Medical Center, Rostock, Germany.
University of Rostock · DE

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Epileptic seizures are frequent in patients with glioblastoma, and anticonvulsive treatment is often necessary. While clinical guidelines recommend all approved anticonvulsants, so far it is still unclear which of the available drugs is the best therapeutic option for treating glioma-associated seizures, also in view of possible anti-tumorigenic effects. In our study, we employed four patient-derived low-passage cell lines of glioblastoma and three cell lines of brain metastases, and challenged these cultures with four anticonvulsants with different mechanisms of action: levetiracetam, valproic acid, carbamazepine and perampanel. Cell proliferation was determined by bromodeoxyuridine incorporation. To further analyze the effects of perampanel, apoptosis induction was measured by caspase 3/7 activation. Glutamate release was quantified and glucose uptake was determined using 18F-fluorodeoxyglucose. Real-time polymerase chain reaction was employed to assess the expression of genes associated with glutamate release and uptake in brain tumor cells. Of the four anticonvulsants, only perampanel showed systematic inhibitory effects on cell proliferation, whereas all other anticonvulsants failed to inhibit glioma and metastasis cell growth in vitro. Metastasis cells were much more resistant to perampanel than glioblastoma cell lines. Glucose uptake was attenuated in all glioblastoma cells after perampanel exposure, whereas cell death via apoptosis was not induced. Extracellular glutamate levels were found to be significantly higher in glioblastoma cell lines as compared to metastasis cell lines, but could be reduced by perampanel exposure. Incubation with perampanel up-regulated glutamine synthetase expression in glioblastoma cells, whereas treatment with valproic acid and levetiracetam downregulated excitatory amino acid transporter-2 expression. Overall, our data suggest that perampanel acts as an anticonvulsive drug and additionally mediated anti-tumorigenic effects.

Indexed as

AnticonvulsantsAntineoplastic AgentsApoptosisBrainBrain NeoplasmsCell Line, TumorCell ProliferationDown-RegulationEpilepsyGlioblastomaGlutamic AcidHumansNitrilesPyridonesReceptors, AMPASeizuresAnticonvulsantsAntineoplastic AgentsGlutamic AcidNitrilesperampanelPyridonesReceptors, AMPAValproic Acid

Identifiers

PMID30716120
PMCPMC6361447
OpenAlexW2914612812

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.